x

Posted 14 February, 2024

BIO-RAD LABORATORIES, INC. appointed new CEO

CEO Change detected for ticker NYSE:BIO in a 8-K filed on 14 February, 2024.


  As previously disclosed, effective at the close of business on November 6, 2023, Ilan Daskal resigned from his position as the Company's Executive Vice-President, Chief Financial Officer and the Company's principal financial officer in order to pursue other opportunities. On February 9, 2024, the Company's board of directors appointed Norman Schwartz, the Company's President and Chief Executive Officer and the Chairman of the Board, as the Company's principal financial officer until a permanent replacement for Mr. Daskal has been appointed.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BIO-RAD LABORATORIES, INC.
Health Care/Life Sciences • Medical Equipment/Supplies
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Market Cap
$9.81B
View Company Details
BIO-RAD LABORATORIES, INC. by TradingView
Relevant filing section
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


As previously disclosed, effective at the close of business on November 6, 2023, Ilan Daskal resigned from his position as the Company's Executive Vice-President, Chief Financial Officer and the Company's principal financial officer in order to pursue other opportunities. On February 9, 2024, the Company's board of directors appointed Norman Schwartz, the Company's President and Chief Executive Officer and the Chairman of the Board, as the Company's principal financial officer until a permanent replacement for Mr. Daskal has been appointed.